It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies. | Haematologica;107(3): 572-573, 2022 03 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies.

Besson, Caroline.

Besson C; Service d'Hematologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, 78150, France; UVSQ, Inserm, CESP, 94805, Villejuif. cbesson@ch-versailles.fr.

Haematologica ; 107(3): 572-573, 2022 03 01.

Article in English | MEDLINE | ID: covidwho-1714972

Subject(s)

COVID-19; Neoplasms; Antigens, CD20; COVID-19/prevention & control; Humans; SARS-CoV-2; Vaccination

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Topics: Vaccines Limits: Humans Language: English Journal: Haematologica Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Topics: Vaccines Limits: Humans Language: English Journal: Haematologica Year: 2022 Document Type: Article